Table 3.

Motor function and test results for patients with PD divided after the measured medicine effect.

Variable	PD LDCT ≤ 30% (n = 21)	PD LDCT > 30% (n = 16)	p value
Hand dominance, right/left (%)	17/4 (81, 19)	13/3 (81.2, 18.8)	1.000
Motor asymmetry, yes/no	16/5 (76.2, 23.8)	14/2 (87.5, 12.5)	0.675
Tremor as first symptom, yes/no	7/14 (33.3, 66.7)	9/7 (56.2, 43.8)	0.196
UPDRS total on	42 [15, 72]	34.5 [17, 53]	0.025
UPDRS-I	3 [0, 7]	2 [1, 6]	0.913
UPDRS-II	12 [3, 20]	10.5 [2, 18]	0.380
UPDRS-III motor score
Off score	30 [10, 59]	34 [19, 49]	0.634
On score	26 [8, 57]	16.5 [6, 29]	0.006
Motor improvement in %	17.0 [−20.0, 27.6]	42.9 [31.0, 83.8]	<0.001
UPDRS-IV	2 [0, 9]	4 [0, 9]	0.023
Total LEDD (mg/day)	550 [140, 1140]	612 [164, 1460]	0.951
Modified Hoehn and Yahr stage	2 [1, 3]	2 [2, 3]	0.973
ADL	80 [60, 90]	90 [80, 90]	0.211
BDI	8 [0, 19]	8.5 [0, 16]	1.000

PD LDCT ≤ 30%, PD acute levodopa challenge test with a change less than or equal to 30% improvement of UPDRS III; PD LDCT > 30%, PD acute levodopa challenge test with more than 30% improvement of UPDRS III; UPDRS, Unified Parkinson's Disease Rating Scale; LEDD, Levodopa Equivalent Daily Dose; ADL, Schwab and England Activities of Daily Living Scale; BDI, Beck's Depression Inventory. The total daily L-dopa equivalent dose (LEDD) for each patient is calculated by using the conversion factors form Tomlinson [10]. We did not distinguish between L-dopa medicines with immediate or controlled release. All values are reported as the median (minimum, maximum) or absolute frequency (relative frequency in %).